However, the lack of statistical significance in the ALTTO phase III pivotal trial,25 which evaluated the combination the addition of lapatinib to trastuzumab compared to trastuzumab, precluded the approval of lapatinib for the treatment of early-stage HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.